A Phase I Study to Evaluate the Safety and Pharmacokinetics of RO7890597 Following Single and Multiple Ascending Doses, and the Effects of Food, Proton-Pump Inhibition, And CYP3A Inhibition in Healthy Adult Volunteers

Summary

This study will evaluate the safety, pharmacokinetics (PK), and activity of single and multiple doses of RO7890597 compared with placebo in healthy volunteers. The study includes single ascending dose (SAD) stage, multiple ascending dose (MAD) stage, food-effect and proton pump inhibitor (PPI) stages, and a supplemental drug-drug interaction (DDI) stage.

Eligibility

Age range

18–65 years

Sex

All

Healthy volunteers

Yes

Interventions

• Drug
  RO7890597

  Participants will receive RO7890597 as per the schedule described in the protocol.

• Drug
  Placebo

  Participants will receive matching placebo as per the schedule described in the protocol.

• Drug
  Rabeprazole

  Participants will receive rabeprazole as per the schedule described in the protocol.

• Drug
  Itraconazole

  Participants will receive itraconazole as per the schedule described in the protocol.

Location